Halozyme Q4 2025: Revenue Growth Masked by Significant Non-GAAP Earnings Miss
Halozyme Therapeutics reported Q4 2025 revenue of $451 million, beating expectations on the back of strong royalty growth from its ENHANZE platform. However, a surprise Non-GAAP EPS loss of $0.24, missing estimates by over $2.00, highlights intensifying operational costs and strategic shifts in its drug delivery portfolio.